Terms: = Leukemia AND SF3B1, ENSG00000115524, 23451, O75533, SF3b155, SAP155, PRPF10, PRP10 AND Diagnosis
78 results:
1. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.
Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
[TBL] [Abstract] [Full Text] [Related]
2. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
3. IMMUNOPHENOTYPE OF LEUKEMIC CELLS IN CHRONIC LYMPHOCYTIC leukemia PATIENTS WITH NOTCH1 AND sf3b1 GENE MUTATIONS.
Golyarnik N; Абраменко І; Movchan G; Martina Z; Dyagil I; Chumak A; Bazyka D
Exp Oncol; 2023 Dec; 45(3):322-327. PubMed ID: 38186023
[TBL] [Abstract] [Full Text] [Related]
4. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Tefferi A; Fleti F; Chan O; Al Ali NH; Al-Kali A; Begna KH; Foran JM; Badar T; Khera N; Shah M; Hiwase D; Padron E; Sallman DA; Pardanani A; Arber DA; Orazi A; Reichard KK; He R; Ketterling RP; Gangat N; Komrokji R
Br J Haematol; 2024 Apr; 204(4):1243-1248. PubMed ID: 38083865
[TBL] [Abstract] [Full Text] [Related]
5. How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.
Xian RR
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):51-58. PubMed ID: 38066895
[TBL] [Abstract] [Full Text] [Related]
6. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
Zhang L; Dong H
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
[TBL] [Abstract] [Full Text] [Related]
7. Genomic Mutation Profiles of Patients with Acute Myeloid leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract] [Full Text] [Related]
8. diagnosis and classification of myelodysplastic syndromes.
Hasserjian RP; Germing U; Malcovati L
Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
[TBL] [Abstract] [Full Text] [Related]
9. Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.
Hogg G; Severson EA; Cai L; Hoffmann HM; Holden KA; Fitzgerald K; Kenyon A; Zeng Q; Mooney M; Gardner S; Chen W; Nagan N; Boles D; Parker S; Richman TJ; Letovsky S; Dong H; Anderson SM; Ramkissoon S; Reddy P; Eisenberg M; Chenn A; Jensen TJ
Cancer Genet; 2023 Nov; 278-279():38-49. PubMed ID: 37586297
[TBL] [Abstract] [Full Text] [Related]
10.
Aptullahoglu E; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511096
[TBL] [Abstract] [Full Text] [Related]
11. Computational analysis of peripheral blood smears detects disease-associated cytomorphologies.
de Almeida JG; Gudgin E; Besser M; Dunn WG; Cooper J; Haferlach T; Vassiliou GS; Gerstung M
Nat Commun; 2023 Jul; 14(1):4378. PubMed ID: 37474506
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract] [Full Text] [Related]
13. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.
Jelloul FZ; Quesada AE; Yang RK; Li S; Wang W; Xu J; Tang G; Yin CC; Fang H; El Hussein S; Khoury J; Bassett RL; Garcia-Manero G; Manasanch EE; Orlowski RZ; Qazilbash MH; Patel KP; Medeiros LJ; Lin P
Mod Pathol; 2023 Jun; 36(6):100166. PubMed ID: 36990279
[TBL] [Abstract] [Full Text] [Related]
15. Myelodysplastic Syndromes: New Methods of diagnosis, Prognostication, and Treatment.
Nachtkamp K; Kobbe G; Gattermann N; Germing U
Dtsch Arztebl Int; 2023 Mar; 120(12):203-210. PubMed ID: 36718105
[TBL] [Abstract] [Full Text] [Related]
16. [Clinical analysis of 20 cases of small B lymphocyte proliferative disease with t (14;19) (q32;q13)].
Yang H; Guo R; Shi Y; Qiao C; Wu YJ; Fan L; Xu W; Miao KR; Li JY; Qiu HR
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):674-679. PubMed ID: 36709153
[No Abstract] [Full Text] [Related]
17. Advances in myelodysplastic/myeloproliferative neoplasms.
Prakash S; Arber DA; Bueso-Ramos C; Hasserjian RP; Orazi A
Virchows Arch; 2023 Jan; 482(1):69-83. PubMed ID: 36469102
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic correlation of NOTCH1 and sf3b1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients.
Sadria R; Motamed N; Saberi Anvar M; Mehrabani Yeganeh H; Poopak B
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1757. PubMed ID: 36411516
[TBL] [Abstract] [Full Text] [Related]
19. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.
Eckardt JN; Röllig C; Metzeler K; Kramer M; Stasik S; Georgi JA; Heisig P; Spiekermann K; Krug U; Braess J; Görlich D; Sauerland CM; Woermann B; Herold T; Berdel WE; Hiddemann W; Kroschinsky F; Schetelig J; Platzbecker U; Müller-Tidow C; Sauer T; Serve H; Baldus C; Schäfer-Eckart K; Kaufmann M; Krause S; Hänel M; Schliemann C; Hanoun M; Thiede C; Bornhäuser M; Wendt K; Middeke JM
Haematologica; 2023 Mar; 108(3):690-704. PubMed ID: 35708137
[TBL] [Abstract] [Full Text] [Related]
20. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
[TBL] [Abstract] [Full Text] [Related]
[Next]